ERBB2 and neoplasm: Taken together, these results suggest that FASN may function as a tumor-cell-intrinsic marker of immune resistance that can be targeted to (re)sensitize highly aggressive cancer subtypes (e.g., HER2 + /PD-L1-overexpressing basal/HER2 breast cancer) to T-cell immunity.